Wikisage, the free encyclopedia of the second generation, is digital heritage
Fabry disease: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
[https://link.springer.com/article/10.1007%2Fs12551-018-0432-5 Anderson-Fabry disease in heart failure] | [https://link.springer.com/article/10.1007%2Fs12551-018-0432-5 Anderson-Fabry disease in heart failure] | ||
Galafold [summary of product characteristics]. Buckinghamshire, UK; Amicus Therapeutics UK Ltd: 2017 | |||
<references/> | <references/> |
Revision as of 00:49, 11 August 2018
Fabry disease is a genetic condition involving lysosomal storage (E75.2)[1]is an X-linked disorder caused by alpha-galactosidase A deficiency [2]
migalastat or 1-deoxygalactonojirimycin received an orphan drug approval [3]
- improves diarrhea
https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0813-7 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY
Anderson-Fabry disease in heart failure
Galafold [summary of product characteristics]. Buckinghamshire, UK; Amicus Therapeutics UK Ltd: 2017